Can you really preserve muscle mass while losing weight on GLP-1s?

What did @realdrbae actually say?

The creator, who identifies as a doctor, argued that bodybuilder Dawson Weiss using retatrutide while maintaining an impressive physique proves that GLP-1 receptor agonists don't inevitably cause muscle and bone loss. The core claim: "lifestyle eating right, exercising can help you minimize lean body mass loss. It's not a predetermined fate." They also called tirzepatide "the closest thing to a magic pill" and mentioned that gym culture is increasingly using GLP-1s to get shredded.

The headline claim, that muscle loss on GLP-1s is not a predetermined fate, is actually defensible. The problem is how they got there. Using a single high-profile bodybuilder as evidence is not how science works, and calling any drug a "magic pill" from a medical professional's platform is the kind of framing that should make anyone uncomfortable.

Does the science back this up?

Yes, partially, and the partial part matters. Randomized controlled trials do confirm that GLP-1 agonists cause disproportionate lean mass loss alongside fat loss. The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide users lost roughly 40% of their total weight loss from lean mass, not just fat. That is a real concern, not a myth to be waved away with a bodybuilder photo.

However, resistance training does appear to meaningfully offset this. Lim et al. (2022, Obesity Reviews) and subsequent analyses have consistently found that individuals who maintain protein intake and resistance training during GLP-1 therapy preserve significantly more lean mass than sedentary users. The SURMOUNT-1 trial data on tirzepatide (Jastreboff et al., 2022, NEJM) showed similar patterns. So the claim that lifestyle intervention matters is real, but "minimizes" is doing a lot of work here. Even active users still lose some lean mass. It is a mitigation strategy, not a prevention strategy.

What did they get wrong (or right)?

They got the broad strokes right: muscle loss on GLP-1s is not inevitable to the degree that people fear, and lifestyle factors genuinely shift the outcome. Credit where it is due.

But several things here are worth flagging directly. First, retatrutide has not been approved by the FDA. As of 2024 it remains in Phase 3 trials. Citing a bodybuilder's anecdotal use of an unapproved drug as clinical evidence is not a small error. Second, calling tirzepatide "the closest thing to a magic pill" from a doctor's account sets up unrealistic expectations and contradicts what the clinical literature actually shows about the effort required to maintain results. Third, the logical structure, one bodybuilder is doing fine therefore muscle loss isn't a problem, is a textbook anecdote fallacy. Dawson Weiss is an elite-level athlete with decades of muscle built before any GLP-1 use. Generalizing from him to average patients is a significant stretch.

• Retatrutide is not FDA-approved and has no confirmed dosing guidance for the general public.
• Anecdotal outcomes from professional bodybuilders do not translate to population-level evidence.
• "Magic pill" framing from a medical professional is irresponsible regardless of how effective the drug is.

What should you actually know?

GLP-1 receptor agonists do cause lean mass loss in most users, but the degree varies substantially based on diet and exercise habits. This is not fearmongering and it is not a reason to avoid the medication. It is a reason to go in prepared.

The evidence-based recommendations from multiple obesity medicine groups converge on the same advice: maintain a protein intake of at least 1.2 grams per kilogram of body weight, engage in resistance training at least twice per week, and work with a clinician who monitors body composition rather than just scale weight. Cava et al. (2017, Nutrients) outlined how protein preservation strategies during caloric restriction protect lean mass, findings that apply directly to GLP-1-assisted weight loss. More recent work from Almandoz et al. (2024, Obesity) specifically addressed muscle preservation during GLP-1 therapy and found structured resistance training to be the single most effective intervention.

The takeaway is this: the creator's conclusion is broadly correct, but it arrived via a shortcut that skipped the actual evidence. You deserve the real explanation, not a bodybuilder's Instagram arc as a clinical argument.